MCID: LNG032
MIFTS: 98

Lung Cancer

Categories: Genetic diseases, Cancer diseases, Respiratory diseases

Aliases & Classifications for Lung Cancer

MalaCards integrated aliases for Lung Cancer:

Name: Lung Cancer 57 12 76 25 75 29 6 43 3 15
Non-Small Cell Lung Cancer 12 76 37 29 6
Non-Small Cell Lung Carcinoma 38 12 15 73
Lung Cancer, Protection Against 57 29 6
Lung Carcinoma 12 55 15
Adenocarcinoma of Lung, Response to Tyrosine Kinase Inhibitor in 57 13
Nonsmall Cell Lung Cancer, Somatic 57 13
Lung Cancer, Susceptibility to 57 6
Malignant Neoplasm of Lung 25 73
Nonsmall Cell Lung Cancer 57 75
Alveolar Cell Carcinoma 75 29
Carcinoma of Lung 12 73
Lung Neoplasms 25 73
Lung Neoplasm 12 76
Nsclc 12 55
Nonsmall Cell Lung Cancer, Response to Tyrosine Kinase Inhibitor in 57
Nonsmall Cell Lung Cancer, Susceptibility to 57
Primary Malignant Neoplasm of Lung 73
Bronchioloalveolar Adenocarcinoma 73
Adenocarcinoma of Lung, Somatic 57
Carcinoma, Non-Small-Cell Lung 44
Carcinoma Non-Small Cell Lung 55
Cancer, Lung, Non-Small Cell 40
Lung Cancer, Resistance to 57
Malignant Tumor of Lung 25
Adenocarcinoma of Lung 75
Lung Malignant Tumors 25
Respiratory Carcinoma 25
Lung Cancer, Somatic 57
Malignant Lung Tumor 25
Pulmonary Carcinoma 25
Pulmonary Neoplasms 25
Cancer of Bronchus 25
Cancer of the Lung 25
Lung Malignancies 25
Pulmonary Cancer 25
Neoplasm of Lung 29
Cancer of Lung 12
Cancer, Lung 40
Cancer Lung 55
Lncr 75

Characteristics:

OMIM:

57
Inheritance:
autosomal recessive


HPO:

32
lung cancer:
Inheritance autosomal recessive inheritance


Classifications:



Summaries for Lung Cancer

MedlinePlus : 43 Lung cancer is one of the most common cancers in the world. It is a leading cause of cancer death in men and women in the United States. Cigarette smoking causes most lung cancers. The more cigarettes you smoke per day and the earlier you started smoking, the greater your risk of lung cancer. High levels of pollution, radiation and asbestos exposure may also increase risk. Common symptoms of lung cancer include A cough that doesn't go away and gets worse over time Constant chest pain Coughing up blood Shortness of breath, wheezing, or hoarseness Repeated problems with pneumonia or bronchitis Swelling of the neck and face Loss of appetite or weight loss Fatigue Doctors diagnose lung cancer using a physical exam, imaging, and lab tests. Treatment depends on the type, stage, and how advanced it is. Treatments include surgery, chemotherapy, radiation therapy, and targeted therapy. Targeted therapy uses substances that attack cancer cells without harming normal cells. NIH: National Cancer Institute

MalaCards based summary : Lung Cancer, also known as non-small cell lung cancer, is related to lung cancer susceptibility 3 and small cell cancer of the lung, and has symptoms including coughing, dyspnea and fever. An important gene associated with Lung Cancer is BRAF (B-Raf Proto-Oncogene, Serine/Threonine Kinase), and among its related pathways/superpathways are Non-small cell lung cancer and MicroRNAs in cancer. The drugs Abraxane and Alimta have been mentioned in the context of this disorder. Affiliated tissues include the lung, lung and brain, and related phenotypes are alveolar cell carcinoma and Decreased viability

OMIM : 57 Lung cancer is the leading cause of cancer deaths in the U.S. and worldwide. The 2 major forms of lung cancer are nonsmall cell lung cancer and small cell lung cancer (see 182280), which account for 85% and 15% of all lung cancers, respectively. Nonsmall cell lung cancer can be divided into 3 major histologic subtypes: squamous cell carcinoma, adenocarcinoma, and large cell lung cancer. Cigarette smoking causes all types of lung cancer, but it is most strongly linked with small cell lung cancer and squamous cell carcinoma. Adenocarcinoma is the most common type in patients who have never smoked. Nonsmall cell lung cancer is often diagnosed at an advanced stage and has a poor prognosis (summary by Herbst et al., 2008). (211980)

UniProtKB/Swiss-Prot : 75 Lung cancer: A common malignancy affecting tissues of the lung. The most common form of lung cancer is non-small cell lung cancer (NSCLC) that can be divided into 3 major histologic subtypes: squamous cell carcinoma, adenocarcinoma, and large cell lung cancer. NSCLC is often diagnosed at an advanced stage and has a poor prognosis.

CDC : 3 Lung cancer is the leading cause of cancer death and the second most common cancer among both men and women in the United States.

Genetics Home Reference : 25 Lung cancer is a disease in which certain cells in the lungs become abnormal and multiply uncontrollably to form a tumor. Lung cancer may not cause signs or symptoms in its early stages. Some people with lung cancer have chest pain, frequent coughing, blood in the mucus, breathing problems, trouble swallowing or speaking, loss of appetite and weight loss, fatigue, or swelling in the face or neck. Additional symptoms can develop if the cancer spreads (metastasizes) into other tissues. Lung cancer occurs most often in adults in their sixties or seventies. Most people who develop lung cancer have a history of long-term tobacco smoking; however, the condition can occur in people who have never smoked.

Disease Ontology : 12 A respiratory system cancer that is located in the lung.

Wikipedia : 76 Lung cancer, also known as lung carcinoma, is a malignant lung tumor characterized by uncontrolled cell... more...

Related Diseases for Lung Cancer

Diseases in the Lung Cancer family:

Lung Benign Neoplasm Lung Carcinoma in Situ

Diseases related to Lung Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 653)
# Related Disease Score Top Affiliating Genes
1 lung cancer susceptibility 3 37.6 BRAF CASP8 EGFR ERBB2 KRAS MAP2K1
2 small cell cancer of the lung 36.3 EGFR MIR21 PIK3CA PTEN
3 lung squamous cell carcinoma 35.1 BRAF EGFR KRAS PIK3CA PTEN
4 colorectal cancer 34.9 BRAF CASP8 EGFR ERBB2 FASLG KRAS
5 adenosquamous cell lung carcinoma 34.7 DDR2 EGFR ERBB2 KRAS PIK3CA
6 breast cancer 34.5 BRAF CASP8 EGFR ERBB2 KRAS MIR145
7 adenocarcinoma 34.5 BRAF EGFR ERBB2 KRAS MAP2K1 PIK3CA
8 squamous cell carcinoma 34.2 BRAF DDR2 EGFR ERBB2 KRAS PIK3CA
9 ovarian cancer 33.9 BRAF CASP8 EGFR ERBB2 KRAS MIR21
10 gastric cancer 33.8 EGFR ERBB2 IRF1 KRAS MIR145 MIR21
11 hepatocellular carcinoma 33.7 CASP8 EGFR FASLG KRAS MAP2K1 MIR145
12 prostate cancer 33.7 CASP8 EGFR ERBB2 KRAS MAP2K1 MIR145
13 esophageal cancer 33.5 EGFR ERBB2 FASLG KRAS MIR21 PIK3CA
14 glioblastoma 33.5 BRAF EGFR ERBB2 MIR21 NRAS PIK3CA
15 gastric adenocarcinoma 33.4 BRAF CASP8 EGFR ERBB2 FASLG KRAS
16 glioma 33.3 BRAF EGFR ERBB2 MIR21 PIK3CA PTEN
17 thyroid cancer 32.9 BRAF KRAS MAP2K1 NRAS PIK3CA PTEN
18 leukemia, chronic lymphocytic 32.8 BRAF CASP8 KRAS MIR145 MIR21 NRAS
19 pancreatic cancer 32.8 EGFR ERBB2 KRAS MAP2K1 MIR21 PIK3CA
20 bladder urothelial carcinoma 32.8 BRAF ERBB2 KRAS MAP2K1 NRAS PIK3CA
21 squamous cell carcinoma, head and neck 32.7 BRAF EGFR ERBB2 MIR21 PIK3CA PTEN
22 cervical cancer 32.6 CASP8 ERBB2 MIR21 PIK3CA PPP2R1B PTEN
23 bladder cancer 32.6 EGFR ERBB2 KRAS MIR145 MIR21
24 glioblastoma multiforme 32.4 EGFR ERBB2 MIR21 PIK3CA PTEN
25 myeloma, multiple 32.4 BRAF CASP8 KRAS NRAS
26 gastrointestinal stromal tumor 32.2 BRAF EGFR KRAS PTEN
27 lymphoma, non-hodgkin, familial 32.0 BRAF CASP8 NRAS PIK3CA
28 ovarian cancer 1 31.9 ERBB2 KRAS PIK3CA
29 estrogen-receptor positive breast cancer 31.9 EGFR ERBB2 PIK3CA
30 langerhans cell histiocytosis 31.9 BRAF MAP2K1 NRAS
31 suppression of tumorigenicity 12 31.9 BRAF PIK3CA PTEN
32 testicular germ cell tumor 31.7 BRAF MIR145 PTEN
33 adrenocortical carcinoma, hereditary 31.6 BRAF NRAS PIK3CA
34 transitional cell carcinoma 31.5 EGFR ERBB2 PTEN
35 paronychia 31.2 EGFR KRAS
36 adamantinoma of long bones 12.6 BRAF CASP8 EGFR ERBB2 KRAS PIK3CA
37 medulloblastoma 12.5 CASP8 EGFR ERBB2 MAP2K1 NRAS PIK3CA
38 breast adenocarcinoma 12.4 CASP8 EGFR ERBB2 KRAS PIK3CA SLC22A18
39 acneiform dermatitis 12.4 EGFR ERBB2 KRAS MAP2K1 NRAS PIK3CA
40 skin melanoma 12.4 BRAF ERBB2 MAP2K1 NRAS PIK3CA PTEN
41 brain cancer 12.4 BRAF CASP8 EGFR NRAS PIK3CA PTEN
42 cholangiocarcinoma 12.4 EGFR ERBB2 KRAS MIR21 PIK3CA PTEN
43 lung cancer susceptibility 1 12.3
44 endometrial cancer 12.3 BRAF EGFR ERBB2 KRAS PIK3CA PTEN
45 female reproductive organ cancer 12.3 EGFR ERBB2 KRAS PIK3CA PTEN
46 respiratory system cancer 12.3 EGFR ERBB2 KRAS PIK3CA PTEN
47 oral cavity cancer 12.3 CASP8 EGFR ERBB2 PIK3CA PTEN
48 gastrointestinal system cancer 12.3 EGFR ERBB2 KRAS PIK3CA PTEN
49 renal cell carcinoma, papillary, 1 12.3 BRAF ERBB2 NRAS PIK3CA PTEN
50 cell type cancer 12.2 EGFR ERBB2 KRAS NRAS PTEN

Graphical network of the top 20 diseases related to Lung Cancer:



Diseases related to Lung Cancer

Symptoms & Phenotypes for Lung Cancer

Symptoms via clinical synopsis from OMIM:

57
Lung:
alveolar cell carcinoma
non-small-cell cancer


Clinical features from OMIM:

211980

Human phenotypes related to Lung Cancer:

32
# Description HPO Frequency HPO Source Accession
1 alveolar cell carcinoma 32 HP:0006519

UMLS symptoms related to Lung Cancer:


coughing, dyspnea, fever, hemoptysis, snoring

GenomeRNAi Phenotypes related to Lung Cancer according to GeneCards Suite gene sharing:

26 (show all 20)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.88 BRAF EGFR PIK3CA KRAS
2 Decreased viability GR00106-A-0 10.88 KRAS
3 Decreased viability GR00221-A-1 10.88 EGFR DDR2 KRAS PIK3CA NRAS
4 Decreased viability GR00221-A-2 10.88 DDR2 KRAS PIK3CA MAP3K8
5 Decreased viability GR00221-A-3 10.88 ERBB2 MAP3K8 NRAS
6 Decreased viability GR00221-A-4 10.88 EGFR BRAF ERBB2 DDR2 PIK3CA MAP3K8
7 Decreased viability GR00301-A 10.88 BRAF KRAS MAP3K8
8 Decreased viability GR00342-S-1 10.88 MAP3K8
9 Decreased viability GR00342-S-2 10.88 MAP3K8
10 Decreased viability GR00342-S-3 10.88 MAP3K8
11 Decreased viability GR00381-A-1 10.88 BRAF KRAS
12 Decreased viability GR00402-S-2 10.88 BRAF EGFR DDR2 ERBB2 PIK3CA KRAS
13 Decreased viability in esophageal squamous lineage GR00235-A 9.96 PTEN SLC22A18 BRAF ERBB2 ERCC6 DDR2
14 Decreased cell migration GR00055-A-1 9.83 EGFR BRAF DDR2 KRAS PIK3CA
15 Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance GR00210-A 9.77 PTEN EGFR ERBB2 MAP3K8 NRAS
16 Decreased cella89culturea89derived Hepatitis C virus (HCVcc; Luca89Jc1) infection GR00234-A-2 9.58 EGFR BRAF DDR2
17 Increased cell migration GR00055-A-3 9.55 BRAF EGFR DDR2 PIK3CA KRAS
18 Reduced mammosphere formation GR00396-S 9.5 PTEN BRAF EGFR NRAS KRAS FASLG
19 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.4 SLC22A18 PTEN CASP8 ERCC6 PRKN
20 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.4 SLC22A18 PTEN BRAF CASP8 ERCC6 FASLG

MGI Mouse Phenotypes related to Lung Cancer:

46 (show all 24)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.49 FASLG KRAS IRF1 MAP3K8 PIK3CA NRAS
2 cardiovascular system MP:0005385 10.46 IRF1 MAP2K1 FASLG KRAS MAP3K8 PIK3CA
3 homeostasis/metabolism MP:0005376 10.43 FASLG KRAS IRF1 MAP3K8 PIK3CA NRAS
4 growth/size/body region MP:0005378 10.39 KRAS NRAS MAP2K1 MAP3K8 PIK3CA PRKN
5 integument MP:0010771 10.38 IRF1 MAP2K1 KRAS PIK3CA NRAS PRKN
6 mortality/aging MP:0010768 10.37 FASLG KRAS IRF1 MAP2K1 MAP3K8 PIK3CA
7 endocrine/exocrine gland MP:0005379 10.36 FASLG KRAS IRF1 PIK3CA NRAS MAP2K1
8 immune system MP:0005387 10.33 FASLG KRAS IRF1 NRAS MAP3K8 PIK3CA
9 hematopoietic system MP:0005397 10.31 FASLG KRAS IRF1 NRAS MAP3K8 PTEN
10 neoplasm MP:0002006 10.3 IRF1 MAP2K1 KRAS MAP3K8 PIK3CA NRAS
11 digestive/alimentary MP:0005381 10.25 FASLG KRAS NRAS MAP2K1 MAP3K8 PTEN
12 nervous system MP:0003631 10.25 FASLG KRAS MAP2K1 MAP3K8 PIK3CA PRKN
13 embryo MP:0005380 10.24 KRAS NRAS MAP2K1 PIK3CA PTEN CASP8
14 muscle MP:0005369 10.18 KRAS PIK3CA PRKN PTEN BRAF DDR2
15 craniofacial MP:0005382 10.15 KRAS NRAS MAP2K1 BRAF DDR2 ERBB2
16 liver/biliary system MP:0005370 10.11 FASLG KRAS NRAS PTEN CASP8 BRAF
17 normal MP:0002873 10.1 FASLG KRAS IRF1 NRAS MAP2K1 PRKN
18 limbs/digits/tail MP:0005371 10.07 KRAS NRAS PTEN DDR2 ERBB2 EGFR
19 reproductive system MP:0005389 9.96 FASLG KRAS MAP2K1 PIK3CA PTEN PPP2R1B
20 renal/urinary system MP:0005367 9.87 FASLG KRAS IRF1 PTEN CASP8 BRAF
21 pigmentation MP:0001186 9.77 KRAS NRAS PTEN BRAF EGFR
22 skeleton MP:0005390 9.77 KRAS IRF1 MAP2K1 FASLG PIK3CA NRAS
23 respiratory system MP:0005388 9.76 FASLG KRAS PTEN PRKN CASP8 BRAF
24 vision/eye MP:0005391 9.32 FASLG KRAS MAP2K1 PIK3CA NRAS PTEN

Drugs & Therapeutics for Lung Cancer

FDA approved drugs:

(show all 23)
# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Abraxane 18 49 PACLITAXEL Celgene October 2012
2
Alimta 18 49 PEMETREXED (also Pemetrexed Disodium) Eli Lilly February 2004
3
Avastin 18 49 BEVACIZUMAB Genentech July 2009
4
Cyramza 18 49 RAMUCIRUMAB Eli Lilly April 2014
5
Gemzar 18 49 GEMCITABINE HYDROCHLORIDE Eli Lilly May 1996
6
Gilotrif 18 49 AFATINIB DIMALEATE Boehringer Ingelheim July 2013
7
Hycamtin 18 49 TOPOTECAN HYDROCHLORIDE GlaxoSmithKline/ SmithKline Beecham October 2007/May 1996
8
Iressa 18 49 GEFITINIB AstraZeneca May 2003
9
Keytruda 18 49 PEMBROLIZUMAB Merck September 2014
10
Neutroval 18 tbo-filgrastim Teva Pharmaceutical August 2012
11
Opdivo 18 49 NIVOLUMAB Bristol-Myers Squibb March 2015/ December 2014, March 2015
12
Photodynamic Therapy (& Photofrin) 18 PORFIMER SODIUM Sanofi-aventis January, 1996
13
Photofrin 18 PORFIMER SODIUM QLT January 1998
14
Tarceva 18 49 ERLOTINIB HYDROCHLORIDE Genentech, OSI Pharmaceuticals November, 2004
15
Taxol 18 49 PACLITAXEL Bristol-Myers Squibb August 1997
16
Taxotere 18 49 DOCETAXEL Rhone Poulenc Rorer May 1996
17
Xalkori 18 49 CRIZOTINIB Pfizer August of 2011
18
Xgeva 18 49 DENOSUMAB Amgen June 2013/ November 2010
19
Zometa 18 49 ZOLEDRONIC ACID Novartis August 2001/ February 2002
20
Zykadia 18 49 CERITINIB Novartis April 2014
21
Alecensa 18 ALECTINIB HYDROCHLORIDE Roche December 2015
22
Portazza 18 NECITUMUMAB Eli Lilly November 2015
23
Tagrisso 18 OSIMERTINIB MESYLATE AstraZeneca November 2015

Drugs for Lung Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 949)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Budesonide Approved Phase 4,Phase 2,Phase 3,Phase 1 51333-22-3 63006 5281004
2
Ipratropium Approved Phase 4,Not Applicable 22254-24-6, 60205-81-4 43232
3
Terbutaline Approved Phase 4 23031-25-6 5403
4
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 15663-27-1 84093 441203 2767
5
Gemcitabine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 95058-81-4 60750
6
Pemetrexed Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 150399-23-8, 137281-23-3 446556 60843
7
Paclitaxel Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 33069-62-4 36314
8
Etoposide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 33419-42-0 36462
9
Carboplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 41575-94-4 10339178 498142 38904
10
Docetaxel Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 114977-28-5 148124
11
Gefitinib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 184475-35-2 123631
12
Amiodarone Approved, Investigational Phase 4,Phase 3 1951-25-3 2157
13
Dexmedetomidine Approved, Vet_approved Phase 4,Not Applicable 113775-47-6 68602 5311068
14
Epinephrine Approved, Vet_approved Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1 51-43-4 5816
15
Midazolam Approved, Illicit Phase 4,Phase 1,Not Applicable 59467-70-8 4192
16
Racepinephrine Approved Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1 329-65-7 838
17
Remifentanil Approved Phase 4,Not Applicable 132875-61-7 60815
18
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 50-02-2 5743
19
Dalteparin Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 9005-49-6
20
Heparin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 9005-49-6 772 46507594
21
Vinorelbine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 71486-22-1 60780 44424639
22
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 437-38-7 3345
23
Zoledronic acid Approved Phase 4,Phase 3,Phase 2,Phase 1 118072-93-8 68740
24
Vinblastine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 865-21-4 13342 241903
25
Bevacizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 216974-75-3
26
Everolimus Approved Phase 4,Phase 3,Phase 1,Phase 2 159351-69-6 6442177
27
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1 22916-47-8 4189
28
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 53123-88-9 5284616 6436030 46835353
29
Lidocaine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 137-58-6 3676
30
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 2078-54-8 4943
31
Nedaplatin Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 95734-82-0
32
Ropivacaine Approved Phase 4,Phase 2,Not Applicable 84057-95-4 71273 175805
33
Sunitinib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 341031-54-7, 557795-19-4 5329102
34
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1994-09-7, 94-09-7 2337
35
Amifostine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 20537-88-6 2141
36
Nicotine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 54-11-5 942 89594
37
Acetylcysteine Approved, Investigational Phase 4,Phase 2,Not Applicable 616-91-1 12035
38
Irinotecan Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 97682-44-5, 100286-90-6 60838
39
nivolumab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 946414-94-4
40
Bupivacaine Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 2180-92-9, 38396-39-3 2474
41
Pembrolizumab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 1374853-91-4
42
Aprepitant Approved, Investigational Phase 4,Phase 3,Phase 2 170729-80-3 151165 6918365
43
Fosaprepitant Approved Phase 4,Phase 3,Phase 2 172673-20-0 219090
44
Ondansetron Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 99614-02-5 4595
45
Methylprednisolone Approved, Vet_approved Phase 4,Phase 2,Not Applicable 83-43-2 6741
46
Prednisolone Approved, Vet_approved Phase 4,Phase 2,Not Applicable 50-24-8 5755
47
Morphine Approved, Investigational Phase 4,Phase 2,Not Applicable 57-27-2 5288826
48
Armodafinil Approved, Investigational Phase 4,Phase 1,Phase 2,Not Applicable 112111-43-0
49
Modafinil Approved, Investigational Phase 4,Phase 1,Phase 2,Not Applicable 68693-11-8 4236
50
Alfentanil Approved, Illicit Phase 4 71195-58-9 51263

Interventional clinical trials:

(show top 50) (show all 6679)
# Name Status NCT ID Phase Drugs
1 Efficacy of Nebulized Pulmicort Respules in Primary Lung Cancer Patients With COPD Unknown status NCT02504801 Phase 4 Budesonide
2 Positron Emission Tomography (PET)/Computed Tomography (CT) and Roentgen in Lung Cancer: Evaluation of Patients in General Practice Unknown status NCT00675168 Phase 4
3 Chemotherapy Combined With Yangzhengxiaoji Capsule in Patients With Advanced Non-Small Cell Lung Cancer Unknown status NCT02195453 Phase 4 Yangzhengxiaoji Capsule;Placebo Capsule
4 Endostar Treatment of Advanced Non-small Cell Lung Cancer Multi-center Clinical Research Unknown status NCT02513355 Phase 4 Changchun marina;cisplatin;Taxol;parapl
5 Study of Concurrent Chemo-radiotherapy Combined With Recombinant Human Endostatin for Local Advanced Non-small Cell Lung Cancer (NSCLC) Unknown status NCT01211002 Phase 4 radiotherapy / EP combined with recombinant human endostatin
6 Intercalated Combination of Chemotherapy and Tyrosine Kinase Inhibitors as First-line Treatment for Patients With Non-Small-Cell Lung Cancer Unknown status NCT02031601 Phase 4 Erlotinib;Gefitinib;Icotinib;Docetaxel;Pemetrexed;Platinum (cisplatin or carboplatin);Erlotinib;Gefitinib;Icotinib
7 A Study of Endostar Combined With Chemotherapy Followed by Endostar Maintenance Therapy to Treat Advanced Non-small Cell Lung Cancer (NSCLC) Unknown status NCT01028729 Phase 4 Endostar;Gemcitabine-Cisplatin chemotherapy
8 The Randomized Controlled Clinical Trial of Kushen Injection Unknown status NCT02346318 Phase 4 Compound Kushen Injection
9 Maintenance Gemcitabine in the Chinese Advanced Lung Cancer Unknown status NCT01336192 Phase 4 Gemcitabine;Best supportive care
10 Sequential and Maintenance Icotinib Plus Chemotherapy Versus Icotinib Maintenance After Chemotherapy in Advanced NSCLC Unknown status NCT02194556 Phase 4 Sequential and maintenance icotinib;Maintenance icotinib
11 Amiodarone Prophylaxis for Atrial Fibrillation in Patients Undergoing Surgery for Lung Cancer Unknown status NCT00724581 Phase 4 Amiodarone
12 Safety Evaluation of Dexmedetomidine for EBUS-TBNA Unknown status NCT01381627 Phase 4 Remifentanil;Dexmedetomidine
13 Randomized Study of Preoperative Dexamethasone for Quality of Recovery in VATS Lung Resection Patients Unknown status NCT02275702 Phase 4 Dexamethasone IV;Saline solution
14 Second-line Therapy Study of Combined Chemotherapy and Endostar to Patients With Non-Small Cell Lung Cancer(NSCLC) Unknown status NCT00813332 Phase 4 Endostar(rh recombinant endostatin) plus Docetaxel;Placebo plus Docetaxel
15 Icotinib With Whole Brain Radiation Therapy in NSCLC Patients With Brain Metastases Unknown status NCT01926171 Phase 4 Icotinib plus WBRT
16 First-line Treatment With Icotinib in Elder NSCLC EGFR Mutated Patients Unknown status NCT01646450 Phase 4 Icotinib
17 Sequential Icotinib Plus Chemotherapy Versus Icotinib Alone as First-line Treatment in Stage IIIB/IV Lung Adenocarcinoma Unknown status NCT02103257 Phase 4 Sequential Icotinib Plus Chemotherapy;Icotinib
18 Safety Study of Adjuvant Docetaxel-Carboplatin Treatment for Resected Lung Cancer Completed NCT00883675 Phase 4 Docetaxel-Carboplatin
19 Coagulation Profile in Patients Undergoing Video Assisted Thorascopic Surgery (VATS) for Lung Cancer Completed NCT01741506 Phase 4 Dalteparin (Fragmin®)
20 Effects of Methylprednisolone on Immunological Function and Postoperative Adverse Reaction in Patients With Lung Cancer Completed NCT03393949 Phase 4 Methylprednisolone 1 mg•kg-1;Methylprednisolone 0.5mg•kg-1
21 A Study of Tarceva (Erlotinib) in Elderly Patients With Advanced Non-Small Cell Lung Cancer Completed NCT01196078 Phase 4 erlotinib [Tarceva];vinorelbine
22 A Study in Non-squamous Non Small Cell Lung Cancer in Asian Patients Completed NCT01020786 Phase 4 Pemetrexed;Carboplatin
23 Fentanyl Matrix in Lung Cancer Pain Completed NCT01060137 Phase 4 fentanyl matrix
24 A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Who Present EGFR Mutations Completed NCT01287754 Phase 4 erlotinib [Tarceva]
25 Chemotherapy for Patients With Non-Small Cell Lung Cancer Completed NCT00380718 Phase 4 pemetrexed
26 Assess the Efficacy, Safety and Tolerability of Gefitinib (Iressa® 250mg) as Maintenance Therapy in Locally Advanced or Metastatic (Stage IIIB/IV) Non Small Cell Lung Cancer (NSCLC) Completed NCT00770588 Phase 4 Gefitinib;Placebo
27 Non-small Cell Lung Cancer Registry Completed NCT00099541 Phase 4 zoledronic acid
28 Recombinant Human Endostatin Combined With NP in Neoadjuvant Chemotherapy of Stage ⅢA NSCLC Completed NCT02497118 Phase 4 Endostatin;Vinorelbine;Cisplatin
29 A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Following 4 Cycles of Platinum-based Chemotherapy Without Disease Progression Completed NCT01230710 Phase 4 Erlotinib
30 Efficacy and Safety Study of ZOMETA® in Treatment of High-level NTX Non Small Cell Lung Cancer With Bone Metastasis Completed NCT00762346 Phase 4 zometa
31 Concurrent Chemoradiotherapy (CCRT) With Paclitaxel Plus Cisplatin in LA Non-small-cell Lung Cancer (NSCLC) Completed NCT00686322 Phase 4 Concurrent chemoradiotherapy (paclitaxel plus cisplatin plus radiotherapy)
32 A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer. Completed NCT00451906 Phase 4 Platinum-based chemotherapy;Bevacizumab [Avastin]
33 An Expanded Access Programme With Iressa for Patients With Non-Small-Cell Lung Cancer and Cancer of the Head and Neck Completed NCT00684385 Phase 4 ZD1839
34 "Red Morphine Drops" for Symptomatic Treatment of Dyspnoea in Lung Cancer Completed NCT00338481 Phase 4 Morphine p.o.;Morphine s.c.
35 Pemetrexed Followed by Docetaxel or in Reverse Sequence Completed NCT01442909 Phase 4 Docetaxel and pemetrexed
36 An Expanded Access Program of Tarceva (Erlotinib) in Participants With Advanced Non-Small Cell Lung Cancer (NSCLC) Completed NCT00949910 Phase 4 Erlotinib
37 RAD001 With Paclitaxel and Carboplatin in First Line Treatment of Patients With Advanced Large Cell Lung Cancer With Neuroendocrine Differentiation Completed NCT01317615 Phase 4 RAD001;Paclitaxel;Carboplatin
38 Carotene and Retinol Efficacy Trial Completed NCT00712647 Phase 4 Beta Carotene and Retinol
39 Screening Non Small Cell Lung Cancer With Bone Metastasis and Efficacy and Safety Research of Receiving Bisphosphonates Completed NCT00765687 Phase 4 bisphosphates
40 A Study of First or Second Line Treatment With Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer Completed NCT01066884 Phase 4 erlotinib [Tarceva]
41 Open-label Study in Patients With Metastatic NSLC Treated With Cisplatin, Gemcitabine and Bevacizumab Completed NCT02316327 Phase 4 gemcitabine, cisplatin and bevacizumab
42 Afatinib as Second-line Therapy for Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation Completed NCT02208843 Phase 4 Afatinib
43 Modafinil for the Treatment of Fatigue in Lung Cancer V9.0 Completed NCT00829322 Phase 4 Modafinil;Placebo
44 Anesthesia in Flexible Bronchoscopy for Lung Cancer Diagnostic Completed NCT00440960 Phase 4 propofol;midazolam;alfentanil;lidocaine
45 Progression Free Survival (PFS) Using Erlotinib for Non-Small-Cell Lung Cancer (NSCLC) in Chinese Population Completed NCT02000531 Phase 4 Erlotinib;Chemotherapy
46 Neulasta® in Subjects With Advanced Non-Small-Cell Lung Cancer (NSCLC) During Chemotherapy Completed NCT00115206 Phase 4 Neulasta® (pegfilgrastim)
47 Bio-behavioral Lung Cancer Prevention Program Completed NCT00322205 Phase 4 zyban
48 A Study on the Long Term Survivals in an Expand Access Program (EAP) of Iressa Completed NCT01000740 Phase 4
49 Safety and Efficacy Study of Abraxane in Combination With Carboplatin to Treat Advanced NSCL Cancer in the Elderly Completed NCT02151149 Phase 4 nab-paclitaxel;Carboplatin
50 Cryotherapy Combine Icotinib for Advanced NSCLC Treatment Completed NCT02744664 Phase 4 Icotinib

Search NIH Clinical Center for Lung Cancer

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: carcinoma, non-small-cell lung

Genetic Tests for Lung Cancer

Genetic tests related to Lung Cancer:

# Genetic test Affiliating Genes
1 Non-Small Cell Lung Cancer 29
2 Lung Cancer 29 BRAF CASP8 CYP2A6 DLEC1 EGFR ERBB2 ERCC6 FASLG IRF1 KRAS MAP3K8 PIK3CA PPP2R1B PRKN RASSF1 SLC22A18
3 Lung Cancer, Protection Against 29
4 Neoplasm of Lung 29
5 Alveolar Cell Carcinoma 29

Anatomical Context for Lung Cancer

The Foundational Model of Anatomy Ontology organs/tissues related to Lung Cancer:

19
The Lung

MalaCards organs/tissues related to Lung Cancer:

41
Lung, Brain, Testes, Bone, Lymph Node, T Cells, Endothelial

Publications for Lung Cancer

Articles related to Lung Cancer:

(show top 50) (show all 20150)
# Title Authors Year
1
Characterization of germline mutations in familial lung cancer from the Chinese population. ( 29054765 )
2018
2
Lipid-poor adrenal adenoma versus metastasis in lung cancer: Diagnosis by "comparative enhancement" at multiphasic MR imaging. ( 29970786 )
2018
3
Downregulation of CD24 suppresses bone metastasis of lung cancer. ( 29095550 )
2018
4
RAGE may act as a tumour suppressor to regulate lung cancer development. ( 29421442 )
2018
5
The risk of lung cancer among cooking adults: a meta-analysis of 23 observational studies. ( 29164315 )
2018
6
Brachial plexopathy after stereotactic body radiation therapy for apical lung cancer: Dosimetric analysis and preliminary clinical outcomes. ( 29556585 )
2018
7
Trends in Cardiac Mortality in Patients With Locally Advanced Non-Small Cell Lung Cancer. ( 29353659 )
2018
8
Lung Cancer Mortality in Tuscany from 1971 to 2010 and Its Connections with Silicosis: A Space-Cohort Analysis Based on Shared Models. ( 29796059 )
2018
9
Evaluation of the relationship of erythrocyte membrane Na+/K+-ATPase enzyme activity and tumor response to chemoradiotherapy in patients diagnosed with locally advanced nonsmall cell lung cancer and glioblastoma multiforme. ( 29970705 )
2018
10
A Case Series of Two Patients Presenting With Pericardial Effusion as First Manifestation of Non-Small Cell Lung Cancer With <i>BRAF</i> Mutation and Expression Of PD-L1. ( 29760834 )
2018
11
Diagnosing lung cancer using etoposide microparticles labeled with<sup>99m</sup>Tc. ( 28355888 )
2018
12
Cytostatic hydroxycoumarin OT52 induces ER/Golgi stress and STAT3 inhibition triggering non-canonical cell death and synergy with BH3 mimetics in lung cancer. ( 29247826 )
2018
13
MicroRNA-485-5p suppresses growth and metastasis in non-small cell lung cancer cells by targeting IGF2BP2. ( 29510198 )
2018
14
miR-193b availability is antagonized by LncRNA-SNHG7 for FAIM2-induced tumour progression in non-small cell lung cancer. ( 29131440 )
2018
15
Effect of early use of Chinese herbal products on mortality rate in patients with lung cancer. ( 28942131 )
2018
16
Characteristics of Chinese herbal medicine usage and its effect on survival of lung cancer patients in Taiwan. ( 29100936 )
2018
17
Polysaccharide Functionalized Single Walled Carbon Nanotubes as Nanocarriers for Delivery of Curcumin in Lung Cancer Cells. ( 29448627 )
2018
18
Association Between Clinicopathological Features and Programmed Death Ligand 1 Expression in Non-small Cell Lung Cancer. ( 29374744 )
2018
19
Demographic and clinical correlates of accelerometer assessed physical activity and sedentary time in lung cancer survivors. ( 29226994 )
2018
20
Particle-related exposure, dose and lung cancer risk of primary school children in two European countries. ( 29089125 )
2018
21
Bronchiolitis obliterans organizing pneumonia after stereotactic ablative radiation therapy for lung cancer: A case report. ( 29395853 )
2018
22
Risk factors for disseminated intravascular coagulation in patients with lung cancer. ( 29851300 )
2018
23
Risk-adapted robotic stereotactic body radiation therapy for inoperable early-stage non-small-cell lung cancer. ( 28812120 )
2018
24
Coexistence of Lambert-Eaton myasthenic syndrome and autoimmune encephalitis with anti-CRMP5/CV2 and anti-GABAB receptor antibodies in small cell lung cancer: A case report. ( 29742721 )
2018
25
Lung Cancer and Lung Transplantation. ( 29150033 )
2018
26
Potential influence of interleukin-6 on the therapeutic effect of gefitinib in patients with advanced non-small cell lung cancer harbouring EGFR mutations. ( 29101033 )
2018
27
Induction Cisplatin Docetaxel Followed by Surgery and Erlotinib in Non-Small Cell Lung Cancer. ( 29217088 )
2018
28
Concomitant Non-Small Cell Lung Cancer and Hairy Cell Leukemia in a Patient Harboring BRAF-V600E Mutation in Both Tissues: A Case Report. ( 29606948 )
2018
29
[Analysis of Prognostic Factors and Clinical Characteristics for Patients with Limited Stage Small Cell Lung Cancer with Pleural Effusion]. ( 29357968 )
2018
30
A diphenyldiselenide derivative induces autophagy via JNK in HTB-54 lung cancer cells. ( 28922542 )
2018
31
Rediagnosis of Lung Cancer as NUT Midline Carcinoma Based on Clues From Tumor Genomic Profiling. ( 29752320 )
2018
32
Long non-coding RNA XIST promotes TGF-I^-induced epithelial-mesenchymal transition by regulating miR-367/141-ZEB2 axis in non-small-cell lung cancer. ( 29339211 )
2018
33
Bile duct obstruction in a patient treated with nivolumab as second-line chemotherapy for advanced non-small-cell lung cancer: a case report. ( 28913619 )
2018
34
Quality of life and efficacy of temozolomide combined with whole-brain radiotherapy in patients with brain metastases from non-small-cell lung cancer. ( 29977541 )
2018
35
RUVBL1, a novel C-RAF-binding protein, activates the RAF/MEK/ERK pathway to promote lung cancer tumorigenesis. ( 29545175 )
2018
36
The brigatinib experience: a new generation of therapy for ALK-positive non-small-cell lung cancer. ( 29451020 )
2018
37
Lung abscess following bronchoscopy due to multidrug-resistant Capnocytophaga sputigena adjacent to lung cancer with high PD-L1 expression. ( 29703650 )
2018
38
USP10 inhibits lung cancer cell growth and invasion by upregulating PTEN. ( 28852924 )
2018
39
Well-controlled pleural effusion indicated pseudoprogression after immunotherapy in lung cancer: A case report. ( 29978949 )
2018
40
Effect of silencing TEM8 gene on proliferation, apoptosis, migration and invasion of XWLCa8905 lung cancer cells. ( 29115620 )
2018
41
Retraction: Effect of Long Non-Coding RNA LINC01116 on Biological Behaviors of Non-Small Cell Lung Cancer Cells via the Hippo Signaling Pathway. ( 29377239 )
2018
42
Comparison of Four PD-L1 Immunohistochemical Assays in Lung Cancer. ( 29175115 )
2018
43
miR-342-3p suppresses cell proliferation and migration by targeting AGR2 in non-small cell lung cancer. ( 29107102 )
2018
44
An MRM-Based Cytokeratin Marker Assay as a Tool for Cancer Studies: Application to Lung Cancer Pleural Effusions. ( 29352525 )
2018
45
Prognostic Significance of Pre-Operative Monocyte-to-Lymphocyte Ratio in Lung Cancer Patients Undergoing Radical Surgery. ( 29361036 )
2018
46
Silencing of LncRNA-HOTAIR decreases drug resistance of Non-Small Cell Lung Cancer cells by inactivating autophagy via suppressing the phosphorylation of ULK1. ( 29470986 )
2018
47
Exchanging narratives-A qualitative study of peer support among surgical lung cancer patients. ( 28557003 )
2018
48
Low-dose computed tomography (LDCT) versus other cancer screenings in early diagnosis of lung cancer: A meta-analysis. ( 29979385 )
2018
49
Diffusion-Weighted Imaging of Brain Metastasis from Lung Cancer: Correlation of MRI Parameters with the Histologic Type and Gene Mutation Status. ( 29301782 )
2018
50
The effects of NRF2 modulation on the initiation and progression of chemically and genetically induced lung cancer. ( 28976703 )
2018